ARTV
Artiva Biotherapeutics
$10.32
+$0.29 (+2.89%)Jul 27, 2026
Key metrics
The numbers that frame ARTV today
- Market cap
- $255.08M
- P/E (TTM)
- -2.9
- EV / FCF
- -3.0
- ROIC
- -77.1%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $2.22
- 52wk High
- $14.53
Growth
Revenue and earnings trend for ARTV
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about ARTV
Is Artiva Biotherapeutics a good buy?
Hold. Artiva Biotherapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Artiva Biotherapeutics is selling at a very high price.
What is the market capitalization of ARTV?
Artiva Biotherapeutics's market capitalization is $255.08M.
What is the P/E ratio for ARTV stock?
Artiva Biotherapeutics's current P/E ratio is -2.9.
What is the 52-week high for ARTV stock?
The 52-week high for Artiva Biotherapeutics is $14.53. The current close of $10.32 is 29% below that high.
What is the 52-week low for ARTV stock?
The 52-week low for Artiva Biotherapeutics is $2.22. The current close of $10.32 is 364.9% above that low.
Does ARTV stock pay dividends?
Artiva Biotherapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for ARTV?
Artiva Biotherapeutics's Debt / Equity ratio is 0.12.